Industry News
Aeterna Zentaris Announces Completion Of Patient Recruitment For Phase 3 Trial With Perifosine In Refractory Advanced Colorectal Cancer
Jul 28, 2011
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast Track Designation... Read More
One Tiny Electron Could Be Key To Future Drugs That Repair Sunburn
Jul 27, 2011
Researchers who have been working for nearly a decade to piece together the process by which an enzyme repairs sun-damaged DNA have finally witnessed the entire process in full detail in the laboratory... Read More
Targeting PTEN May Prevent Skin Cancer
Jul 27, 2011
Scientists believe they have identified a role for PTEN, a known tumor suppressor, in removing DNA damage derived from UVB radiation, a known risk factor for non-melanoma skin cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. Yu-Ying He, Ph.D... Read More
Scientists Discover New Pathway To Potential Therapies For Advanced Prostate Cancer
Jul 26, 2011
UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously... Read More
Ovarian And Breast Cancer Counseling And Testing Not Offered According To Guidelines In Physician Practices
Jul 25, 2011
A considerable number of doctors do not appear to offer ovarian and breast cancer counseling, as well as testing services to women at high risk, researchers from the CDC (Centers for Disease Control and Prevention) report in the journal Cancer. Females with the BRCA1 or BRCA2 gene have a much higher chance of developing ovarian or breast cancer compared to other women... Read More
Zytiga(R) Receives Positive Regulatory Recommendation In The European Union For Treatment Of Metastatic Castration Resistant Prostate Cancer
Jul 25, 2011
Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA® (abiraterone acetate) under an accelerated regulatory review procedure... Read More
Predicting Second Cancers After Radiation For Children With Hodgkin Lymphoma
Jul 25, 2011
A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment... Read More
Mismatch Between Cancer Genetics Counseling And Testing Guidelines And Physician Practices
Jul 25, 2011
A new analysis has found that many doctors report that they do not appropriately offer breast and ovarian cancer counseling and testing services to their female patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to encourage these services for high-risk women and discourage them for average-risk women... Read More
Adamis Prostate Cancer Drug APC-100 Granted A Patent In US
Jul 22, 2011
Adamis Pharmaceuticals Corporation (OTCBB: ADMP.OB), today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States. A patent entitled "Chroman-Derived Compounds for the Treatment of Cancer" has been issued... Read More
KRAS Diagnostic Test That Assists With Personalized Treatment Of Colorectal Cancer Receives CE Mark
Jul 22, 2011
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer. The cobas KRAS Mutation Test identifies mutations in the KRAS gene of colorectal cancer tissue that are predictive of individual response to therapy with anti-epidermal growth factor receptor (EGFR) antibody therapies... Read More
Previous Page Next Page